Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes.
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001120:Arginine / Q000494:pharmacology; D001786:Blood Glucose / Q000378:metabolism; D000242:Cyclic AMP / Q000502:physiology; D003921:Diabetes Mellitus, Experimental / Q000473:pathology* / Q000503:physiopathology; D003922:Diabetes Mellitus, Type 1 / Q000473:pathology* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000473:pathology* / Q000503:physiopathology; D004357:Drug Synergism; D005934:Glucagon / Q000378:metabolism; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D005951:Glucose Tolerance Test; D006651:Histocytochemistry; D006801:Humans; D007158:Immunologic Techniques; D066298:In Vitro Techniques; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D010180:Pancreatectomy; D051381:Rats; D011919:Rats, Inbred Strains
D001786:Blood Glucose; D007328:Insulin; D005934:Glucagon; D001120:Arginine; D000242:Cyclic AMP; D005947:Glucose; D015056:1-Methyl-3-isobutylxanthine